The endocannabinoid system and interference with thrombogenesis

Czech version

Authors: T. Kvasnička
Authors‘ workplace: Trombotické centrum, vedoucí prof. MU Dr. Jan Kvasnička, DrSc., Ústav klinické biochemie a laboratorní diagnostiky 1. lékařské fakulty UK a VFN Praha, přednosta prof. MU Dr. Tomáš Zima, DrSc., MBA
Published in: Vnitř Lék 2010; 56(2): 127-129
Category: Reviews

Overview

The endocannabinoid system is an endogenous signaling system that plays a role in the regulation of energy homeostasis and lipid and glucose metabolism‑ all of which can influence cardiometabolic risk. The endocannabinoid system is normally a silent physiologic system that becomes transiently activated, that is, only when needed. Endocannabinoids may also be secreted by the endothelium. Accordingly, there has been interest in the interactions between endocannabinoids and blood cells. There is certainly evidence that endocannabinoids, especially 2‑ arachidonoylglycerol (2‑ AG), may promote platelet activation, indicating that they may participace in regulation of thrombosis and inflammation. Platelets are involved both in the metabolism and release of endocannabinoids, and so it is possible that their circulating levels may be regulated by platelets. 2‑ AG can be considered a new physiologic platelet agonist able to induce full platelet activation and aggregation with a non‑CB₁/ CB₂ receptor‑ mediated mechanism. Not only may endocannabinoids regulate platelet function and possibly lead to thrombogenesis, but they may also influence haematopoesis.

Key words:
endocannabinoids – anandamide – receptors CB₁, CB₂ – platelets – thrombosis – endothelium

Sources

1. Kvasnička T. Význam endokanabinoidního systému v regulaci energetické rovnováhy. Vnitř Lék 2008; 54: 25– 28.

2. Matsuda LA, Lolait SJ, Brownstein MJ et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561– 564.

3. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946– 1949.

4. Mechoulam R, Ben‑ Shabat S, Hanus L et al. Identification of an endogenous 2‑ monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83– 90.

5. Sugiura T, Kondo S, Sukagawa A et al. 2‑ Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89– 97.

6. Gebremedhin D, Lange AR, Campbell WB et al. Cannabinoid CBl receptor of cat cerebral arterial muscle functions to inhibit L‑type Ca2+ channel current. Am J Physiol 1999; 266: H2085– H2093.

7. Liu J, Gao B, Mirshahi F et al. Functional CB₁ cannabinoid receptors in human vascular endothelia I cells. Biochem J 2000; 346: 835– 840.

8. Maccarrone M, Bari M, Lorenzon T et al. Anandamide uptake by human endothelia I cells and its regulation by nitric oxide. J Biol Chem 2000; 275: 13484– 13492.

9. Costa D, Marsicano G, Tschop M et al. The endogenous cannabinoid system affects energy balance via centra I orexigenic drive and peripherallipogenesis. J CIin lnvest 2003; 112: 423– 431.

10. Berdyshev E, Schmid PC, Krebsbach RJ et al. Activation of PAF receptors results in enhanced synthesis of 2‑ arachidonoylglycerol (2‑ AG) in immune cells. FASEB J 2001; 15: 2171– 2178.

11. Begg M, Pacher P, Bàtkai S et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106: 133– 145.

12. Kishimoto S, Kobayashi Y, Oka S et al. 2‑ Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL‑60 cells. J Biochem 2004; 135: 517– 524.

13. Maccarrone M, Del Principe D, Finazzi‑ Agrò A. Endocannabinoids: new physiological (co‑ )agonists of human platelets. Thromb Haemost 2002; 88: 165– 166.

14. Maccarrone M, Bari M, Menichelli Aet al. Human platelets bind and degrade 2‑ arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 2001; 268: 819– 825.

15. Beltramo M, Piomelli D. Carrier‑ mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2‑ arachidonylglycerol. Neuroreport 2002; 11: 231– 235.

16. Bojesen IN, Hansen HS. Membrane transport of anandamide through resealed human red cell membranes. J Lipid Res 2005; 46: 1652– 1659.

17. Braud S, Bon C, Touqui L et al. Activation of rabbit platelets by anandamide through its cleavage into arachidonic acid. FEBS Lett 2000; 471: 12– 16.

18. Beltramo M, Piomelli D. Carrier‑ mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2‑ arachidonylglycerol. Neuroreport 2000; 11: 1231– 1235.

19. Maestroni GJ. The endogenous cannabinoid 2‑ arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. FASEB J 2004; 18: 1914– 1916.

20. Macarrone M, Bari M, Menichelli A et al. Human platelets bind and degrade 2‑ arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 2001; 268: 819– 825.

21. Cupini LM, Bari M, Battista N et al. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 2005; 26: 277– 281.

22. Grosser T, Fries S, FitzGerald GA. Thromboxane generation. Platelet. London: Academic Press 2007: 565– 574.

23. Maccarrone M, Bari M, Principe DD et al. Activation of human platelets by 2‑ arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 2003; 89: 340– 347.

24. Maccarrone M, Bari M, Battista N et al. Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy 2005; 1: 53– 63.

25. Moro L, Reineri S, Piranda D et al. Nongenomic effects of 17b‑ estradiol in human platelets: potentiation of thrombin‑induced aggregation through estrogen receptor band Src kinase. Blood 2005; 105: 115– 121.